Food-derived β-lactoglobulin nanofibrils: An efficacy, safe, and scalable solution to overcome oral insulin delivery challenges.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41377894.
- Also identified by DOI 10.1016/j.bioactmat.2025.11.020 and PMC identifier 12686822.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oral delivery of biologics presents a formidable challenge: achieving high bioavailability without compromising gastrointestinal barrier integrity or clinical scalability-a trilemma that remains unaddressed by existing chemical permeation enhancers, ligand-modified nanoparticles, or exosome platforms. Here, we repurpose β-lactoglobulin (BLG) nanofibrils that resolve this challenge through a unique "enhance-degrade-restore" mechanism. In vivo, these nanofibrils enable oral insulin bioavailability reaching 10.2-12.3 %, and long-term safety studies confirm the absence of intestinal damage. Mechanistic studies reveal that the nanofibrils facilitate Ca<sup>2+</sup> influx-induced calpain activation to enhance paracellular permeability, followed by protease-mediated degradation that ensures timely restoration of barrier integrity. Moreover, nanofibrils maintain full adjuvant activity when integrated into commercial milk products, highlighting their formulation flexibility and robustness. This work introduces a sustainable "waste-to-nanomedicine" strategy that unites high-efficiency peptide delivery with environmentally responsible nanomaterial design.